Please assess the completion status of the following clinical trial:

Trial Title: Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prostate biopsy positive for cancer; clinically localized T1 and T2 stage disease expected, with biopsy specimen available for baseline biomarker measurements~* Scheduled for a radical prostatectomy~* Willing to sign an Institutional Review Board (IRB)-approved informed consent document and adhere to the protocol~* Willing and able to take oral medications~* Willing to refrain from drinking any kind of tea (including herbal tea) or using supplements containing green tea constituents for the duration of the study~Exclusion Criteria:~* Prior hormonal or surgical therapy for prostate cancer; including prior brachytherapy or radiation therapy~* Recent consumption of tea (six or more cups per day) or use of supplements containing green tea within one week of randomization~* Signs or symptoms of progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease~* Serum creatinine \>= 1.5 x upper limit of normal (ULN)~* Alanine aminotransferase (ALT) \>= ULN~* Aspartate aminotransferase (AST) \>= ULN~* Alkaline phosphatase (ALP) \>= ULN~* Albumin (ALB) =\< lower limit of normal (LLN)~* Total bilirubin \>= ULN~* Known malignancy at any site within the last five years; with the exception of basal cell carcinoma (BCC)~* Participation in a research trial within the past three months~* Any condition that would interfere with the ability to give informed consent or comply with the study protocol~* Hypersensitivity to tea products or any of the inactive ingredients found in the drug product capsules~* Concomitant use of at least 400 mg per day of a nonsteroidal anti-inflammatory (NSAID) agent two or more times per week

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Polyphenon E) (Type: EXPERIMENTAL): Patients receive defined green tea catechin extract PO once daily QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
- Arm II (placebo) (Type: PLACEBO_COMPARATOR): Patients receive placebo PO QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.

Based on this trial design, predict the completion outcome and termination type (if applicable).